These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36370317)

  • 1. Two pediatric cases of severe hemophilia A in which emicizumab prophylaxis failed to prevent traumatic extra-articular hemorrhage.
    Yamada Y; Nakajima Y; Ohara A; Wakita E; Shimizu K; Shimonishi N; Furukawa S; Ogiwara K; Takeyama M; Nogami K
    Int J Hematol; 2023 Apr; 117(4):607-612. PubMed ID: 36370317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.
    Nakajima Y; Nogami K; Yada K; Furukawa S; Noguchi-Sasaki M; Hirata M; Shima M
    Thromb Haemost; 2020 Jun; 120(6):968-976. PubMed ID: 32384547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.
    Nakajima Y; Mizumachi K; Shimonishi N; Furukawa S; Yada K; Ogiwara K; Takeyama M; Shima M; Nogami K
    Int J Hematol; 2022 Apr; 115(4):489-498. PubMed ID: 35043383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peri-operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis.
    Yagyuu T; Furukawa S; Zaizen M; Yata S; Imada M; Nogami K; Kirita T
    Haemophilia; 2023 Jan; 29(1):172-179. PubMed ID: 36163647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A.
    Takeyama M; Matsumoto N; Abe H; Harada S; Ogiwara K; Furukawa S; Shimonishi N; Nakajima Y; Yada K; Soeda T; Nogami K
    Pediatr Blood Cancer; 2023 Oct; 70(10):e30590. PubMed ID: 37467119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A.
    Onishi T; Harada S; Shimo H; Tashiro Y; Soeda T; Nogami K
    Haemophilia; 2023 Nov; 29(6):1529-1538. PubMed ID: 37766492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
    Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
    Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
    Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A.
    Takeyama M; Furukawa S; Yada K; Ogiwara K; Shimonishi N; Nakajima Y; Mizumachi K; Noguchi-Sasaki M; Shima M; Nogami K
    Thromb Haemost; 2021 Oct; 121(10):1289-1298. PubMed ID: 33641138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease in in vivo coagulant potential of emicizumab in a patient with hemophilia A and inhibitor complicated with infectious mononucleosis.
    Furukawa S; Ogiwara K; Yada K; Takeyama M; Niino T; Shima M; Keiji N
    Blood Coagul Fibrinolysis; 2023 Mar; 34(2):122-128. PubMed ID: 36719809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis.
    Mizumachi K; Tsumura Y; Nakajima Y; Koh K; Nogami K
    Int J Hematol; 2021 Jun; 113(6):930-935. PubMed ID: 33566316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial.
    Ogiwara K; Taki M; Suzuki T; Takedani H; Matsushita T; Amano K; Matsumoto M; Nishio K; Shima M; Kasahara M; Nogami K
    BMJ Open; 2022 Feb; 12(2):e056922. PubMed ID: 35177463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors.
    Cafuir L; Estrin A; Chen E; Hinds D; Prince P; Thorburn J; Mead H; Kempton CL
    J Med Econ; 2022; 25(1):984-992. PubMed ID: 35848992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy/effectiveness and safety of emicizumab prophylaxis of people with hemophilia A: a systematic review and meta-analysis.
    Muniz RL; Camelo RM; Araújo MS; Barbosa MM; Guerra AA; Acurcio FA; Alvares-Teodoro J
    Expert Rev Hematol; 2023; 16(12):1087-1097. PubMed ID: 38066708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma.
    Takeyama M; Furukawa S; Onishi T; Noguchi-Sasaki M; Shima M; Nogami K
    Pediatr Blood Cancer; 2022 Jul; 69(7):e29731. PubMed ID: 35441786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.